Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241383 | PMC |
| http://dx.doi.org/10.1016/j.jaad.2020.05.078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on 'Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder' by Wobser et al.
Br J Dermatol
December 2024
Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immu-notherapy (HIPI), Paris, France.
Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma.
Br J Dermatol
November 2024
Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder: a benign or malignant process?
Br J Dermatol
October 2024
Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands.
Onychomatricoma is not a subtype of superficial acral fibromyxoma: Can immunohistochemistry help in the differential diagnosis?
J Cutan Pathol
June 2024
Department of Cellular Pathology, Maidstone Hospital, Kent, UK.
Relationships between tumor thickness and the risk of sentinel node metastasis in acral and non-acral melanoma.
Int J Dermatol
November 2023
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, 060-8543, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!